Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13346303 | 0.80 | KMT2A (0.30) | KMT2A | |
| SCHEMBL13008704 | 0.80 | KMT2A (0.30) | KMT2A | |
| SCHEMBL13130572 | 0.79 | — | — | |
| SCHEMBL13130592 | 0.79 | TSHR (0.31) | KMT2A | |
| SCHEMBL13009009 | 0.78 | KMT2A (0.31) | KMT2A | |
| SCHEMBL9040315 | 0.77 | HSD11B1 (0.32) | — | |
| SCHEMBL13009423 | 0.77 | — | — | |
| SCHEMBL13411259 | 0.77 | GAA (0.33) | GAAL3MBTL1 | |
| SCHEMBL13474854 | 0.77 | — | — | |
| SCHEMBL352949 | 0.77 | GAA (0.36) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272002-A1 | PHOTOREDOX PROTEIN MODIFICATION | THE ROSALIND FRANKLIN INSTITUTE (GB) | 2023-08-31 | — | — | US | disclosed |
| EP-2855630-B1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-8471031-B2 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8471031-B2 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8471031-B2 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| CN-101484422-B | Process for the preparation of sterically hindered nitroxyl ethers | CIBA HOLDING INC | 2012-07-11 | — | — | CN | disclosed |
| EP-2035381-B1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | BASF SE (DE) | 2010-12-29 | — | — | EP | disclosed |
| EP-2035381-B1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | BASF SE (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| CN-101484422-A | Process for the preparation of sterically hindered nitroxyl ethers | CIBA HOLDING INC (CH) | 2009-07-15 | — | — | CN | disclosed |
| EP-2035381-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | Ciba Holding Inc. (CH) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003602-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | CIBA HOLDING INC. (CH) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003602-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | CIBA HOLDING INC. (CH) | 2008-01-10 | — | — | WO | disclosed |
| CN-1230424-C | Hydroxy substituted N-alkoxy hindered amine | CIBA SC HOLDING AG (CH) | 2005-12-07 | — | — | CN | disclosed |
| CN-1273241-A | Hydroxy substituted N-alkoxy hindered amine | CIBA SC HOLDING AG (CH) | 2000-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272002-A1 | PHOTOREDOX PROTEIN MODIFICATION | PPOX, CACYBP, BRI3BP | GAA 4457/4885L3MBTL1 2997/4885KMT2A 3404/4885 |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | PPOX, CBR1, CBR3 | GAA 1862/4885L3MBTL1 1824/4885KMT2A 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.